TORONTO, ON / ACCESSWIRE / June 15, 2015 / CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company") a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced it has entered into an ECG device and software distribution and marketing agreement with Minnesota based IntriCon Corporation ("IntriCon"; NASDAQ symbol "IIN").
CardioComm Solutions will benefit directly from devices sales as an authorized distributor of the Sirona devices with preferred distributor pricing which will translate into competitive pricing to the Company's Global ECG Management Solution for Windows ("GEMS(TM) WIN") customer base. Hardware sales will commence in Canada and the USA with the anticipation that the Sirona device will have the needed CE Mark provided for sales to be possible in Europe by the end of this year.
Under the agreement, CardioComm Solutions has developed a custom interoptability between IntriCon's Sirona ECG device and the Company's proprietary wireless GEMS(TM) WIN module and ("GEMS(TM) AIR"). This integration will allow GEMS(TM) WIN licensors to incorporate the Sirona device into their business operations for use alongside their existing ambulatory ECG/arrhythmia monitoring device inventory. For customers under an active GEMS(TM) AIR software license, the appropriate Sirona driver version update will be provided at no cost.
What's new? In addition to supporting traditional trans-telephonic ECG transmission, the Sirona device can connect via Android and iPhone mobile devices allowing a patient's own Smartphone to support wireless transmission of their Sirona acquired ECG data. Use of patient Smartphones would provide savings opportunities for GEMS(TM) AIR customers who no longer would be required to purchase more expensive ambulatory ECG monitoring devices with built-in GSM capabilities. Where a patient does not have a Smartphone, operators may provide a locked Smartphone for use with the Sirona device, a common practice with ECG service providers.
The Sirona-GEMS(TM) based ECG management does not involve the storage of any patient data on the Smartphone at any time and will be available to the North American market prior to the end of Q3 2015. GEMS(TM) WIN is the only FDA cleared and Health Canada approved, ECG management software platform available for sale that supports the Sirona device in North America.
CardioComm Solutions has previously reported requirements for ECG service providers to replace their existing ECG management solutions to versions that are WIN 7 and Server 2008 compatible. CardioComm Solutions released its GEMS(TM) WIN software upgrade to the arrhythmia monitoring market in response to the 2014 discontinuation of XP support by Microsoft and the soon to occur discontinuation of Server 2003 in July, 2015. The GEMS(TM) WIN family of products is a Windows 7 and Server 2008 compatible version of the Company's FDA cleared, Health Canada approved and CE Marked ECG management software and includes a specific module (GEMS(TM) AIR) that enables the use of the Sirona as well and other digital wireless event recorders.
To learn more about the CardioComm Solutions products and devices compatible with GEMS(TM) WIN please see the Company's website www.cardiocommsolutions.com or contact the Company at sales@cardiocommsolutions.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: CardioComm Solutions, Inc.